We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug development: Mix and match.
- Authors
Scudellari, Megan
- Abstract
The article focuses on the development of chemotherapeutic agents designed to treat advanced colorectal cancer (CRC). It states the average overall survival for advanced CRC has expanded from 15 to 30 months with new drugs only providing incremental benefits. It talks about four classes of drugs that treat metastatic CRC, including kinase inhibitors, EGFR receptor antibodies, cytotoxic chemotherapy, and drugs that inhibit new blood vessel growth. It comments on research into CRC biomarkers.
- Subjects
COLON cancer treatment; CANCER chemotherapy; METASTASIS; KINASE inhibitors; RECEPTOR antibodies; ANTINEOPLASTIC agents; NEOVASCULARIZATION inhibitors; BIOMARKERS
- Publication
Nature, 2015, Vol 521, Issue 7551, pS12
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/521S12a